New inhaled treatment tested for scarred lungs

NCT ID NCT05537025

Completed Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested the safety and effects of an inhaled drug called ARO-MMP7 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. The goal was to see if the drug was safe and how it behaved in the body. The study involved 105 participants and was an early-stage trial to gather initial data.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site 1

Copenhagen, DA-2100, Denmark
Research Site 1

Ancona, 60126, Italy
Research Site 1

Auckland, 1010, New Zealand
Research Site 1

Ulsan, 44033, South Korea
Research Site 1

Barcelona, 08017, Spain
Research Site 1

Birmingham, B15 2GW, United Kingdom
Research Site 2

Odense, DK-5000, Denmark
Research Site 2

Florence, 50134, Italy
Research Site 2

Christchurch, 08011, New Zealand
Research Site 2

Seoul, 05505, South Korea
Research Site 2

Oviedo, 33011, Spain
Research Site 2

Edinburgh, EH16 4SA, United Kingdom
Research Site 3

Milan, 20122, Italy
Research Site 3

Soeul, 21565, South Korea
Research Site 3

Santander, Cantabria, 39008, Spain
Research Site 3

Manchester, M8 5RB, United Kingdom
Research Site 4

Milan, 20122, Italy
Research Site 4

Manchester, M23 9QZ, United Kingdom
Research Site 5

Milan, 20123, Italy

Conditions

Explore the condition pages connected to this study.

IDIOPATHIC PULMONARY FIBROSIS